Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides  genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods. The segment offers its products primarily to milling and grain, meat and poultry, prepared foods and ingredients, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products, and genomics testing services marketed through veterinarians, retailers, livestock producers, and animal health product distributors, for the animal safety market. The segment offers its products for companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

Neogen Corporation

The NASDAQ 100 After Hours Indicator is down -2.43 to 23,711.33. The total After hours volume is currently 129,178,808 shares traded.
The following are the most active stocks for the after hours session:
Vanguard Intermediate-Term Corporate Bond ETF (VCIT) is unchanged at $82.96, with 9,316,788 shares traded. This represents a 5.47% increase from its 52 Week Low.
Twilio Inc. (TWLO) is +0.45 at $105.50, with 7,167,052 shares traded. As reported by Zacks, the current mean recommendation for TWLO is in the "buy range".
Sitio Royalties Corp. (STR) is -0.04 at $18.08, with 6,193,205 shares traded. STR's current last sale is 66.96% of the target price of $27.
NVIDIA Corporation (NVDA) is -0.05 at $181.96, with 5,844,362 shares traded. As reported by Zacks, the current mean recommendation for NVDA is in the "buy range".
Opendoor Technologies Inc (OPEN) is +0.04 at $3.82, with 4,322,985 shares traded. OPEN's current last sale is 402.11% of the target price of $0.95.
Bank of America Corporation (BAC) is -0.0191 at $47.90, with 3,248,573 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2025. The consensus EPS forecast is $0.96. As reported by Zacks, the current mean recommendation for BAC is in the "buy range".
Johnson & Johnson (JNJ) is unchanged at $176.25, with 3,103,798 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2025. The consensus EPS forecast is $2.55. JNJ's current last sale is 100.71% of the target price of $175.
Neogen Corporation (NEOG) is unchanged at $5.54, with 3,027,610 shares traded. NEOG's current last sale is 85.23% of the target price of $6.5.
Palo Alto Networks, Inc. (PANW) is +9.3299 at $185.50, with 2,915,140 shares traded. As reported by Zacks, the current mean recommendation for PANW is in the "buy range".
Viper Energy, Inc. (VNOM) is +0.16 at $37.40, with 2,425,662 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2025. The consensus EPS forecast is $0.34. As reported in the last short interest update the days to cover for VNOM is 9.171964; this calculation is based on the average trading volume of the stock.
Kenvue Inc. (KVUE) is unchanged at $21.10, with 2,217,646 shares traded. KVUE's current last sale is 94.83% of the target price of $22.25.
CNH Industrial N.V. (CNH) is unchanged at $12.20, with 2,004,227 shares traded. CNH's current last sale is 81.33% of the target price of $15.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

After Hours Most Active for Aug 18, 2025 : VCIT, TWLO, STR, NVDA, OPEN, BAC, JNJ, NEOG, PANW, VNOM, KVUE, CNH

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR Portfolio S&P 600 Small Cap ETF (Symbol: SPSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $51.44 per unit.
With SPSM trading at a recent price near $43.25 per unit, that means that analysts see 18.94% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of SPSM's underlying holdings with notable upside to their analyst target prices are ProPetro Holding Corp (Symbol: PUMP), LiveRamp Holdings Inc (Symbol: RAMP), and Neogen Corp (Symbol: NEOG). Although PUMP has traded at a recent price of $4.82/share, the average analyst target is 71.16% higher at $8.25/share. Similarly, RAMP has 58.73% upside from the recent share price of $26.46 if the average analyst target price of $42.00/share is reached, and analysts on average are expecting NEOG to reach a target price of $7.50/share, which is 47.64% above the recent price of $5.08. Below is a twelve month price history chart comparing the stock performance of PUMP, RAMP, and NEOG:
Below is a summary table of the current analyst target prices discussed above:
Name
Symbol
Recent Price
Avg. Analyst 12-Mo. Target
% Upside to Target
ProPetro Holding Corp
PUMP
$4.82
$8.25
71.16%
LiveRamp Holdings Inc
RAMP
$26.46
$42.00
58.73%
Neogen Corp
NEOG
$5.08
$7.50
47.64%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

SPSM's Holdings Could Mean 19% Gain Potential

(RTTNews) - Neogen Corporation (NEOG), a global provider of food safety solutions, has completed the sale of its global cleaners and disinfectants business to Kersia Group for $130 million in cash, with additional contingent payments based on future performance.
The move is part of Neogen's strategic plan to sharpen its focus on core operations. The proceeds from the sale will be used to repay $100 million in debt this quarter, which is expected to reduce net leverage by approximately 0.4x on a pro forma basis.
Neogen CEO John Adent stated that the transaction is a significant step in streamlining the company's operations and aligning its focus with its core business. He expressed confidence in Kersia as a long-term steward of the divested business and appreciation for their cooperation during the transition.
Friday NEOG closed at $4.74, or 2.4691% lower on the NasdaqGS.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Neogen Sells Cleaners And Disinfectants Unit To Kersia For $130 Mln

Investors eyeing a purchase of Neogen Corp (Symbol: NEOG) stock, but cautious about paying the going market price of $5.58/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $5 strike, which has a bid at the time of this writing of 70 cents. Collecting that bid as the premium represents a 14% return against the $5 commitment, or a 31% annualized rate of return (at Stock Options Channel we call this the YieldBoost).
Selling a put does not give an investor access to NEOG's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $5 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Neogen Corp sees its shares decline 10.9% and the contract is exercised (resulting in a cost basis of $4.30 per share before broker commissions, subtracting the 70 cents from $5), the only upside to the put seller is from collecting that premium for the 31% annualized rate of return.
Below is a chart showing the trailing twelve month trading history for Neogen Corp, and highlighting in green where the $5 strike is located relative to that history:
The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the October put at the $5 strike for the 31% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Neogen Corp (considering the last 249 trading day closing values as well as today's price of $5.58) to be 61%. For other put options contract ideas at the various different available expirations, visit the NEOG Stock Options page of StockOptionsChannel.com.
In mid-afternoon trading on Monday, the put volume among S&P 500 components was 810,250 contracts, with call volume at 810,250, for a put:call ratio of 0.72 so far for the day, which is above normal compared to the long-term median put:call ratio of .65. In other words, if we look at the number of call buyers and then use the long-term median to project the number of put buyers we'd expect to see, we're actually seeing more put buyers than expected out there in options trading so far today. Find out which 15 call and put options traders are talking about today.
Also see:
Thermo Fisher Scientific YTD Return
MTSN Historical Stock Prices
MCY Historical Stock Prices
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Commit To Buy Neogen At $5, Earn 31% Annualized Using Options

Neogen (NEOG) came out with quarterly earnings of $0.10 per share, missing the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -23.08%. A quarter ago, it was expected that this maker of medical testing kits would post earnings of $0.11 per share when it actually produced earnings of $0.11, delivering no surprise.
Over the last four quarters, the company has not been able to surpass consensus EPS estimates.
Neogen, which belongs to the Zacks Medical - Products industry, posted revenues of $220.98 million for the quarter ended February 2025, missing the Zacks Consensus Estimate by 0.92%. This compares to year-ago revenues of $228.81 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Neogen shares have lost about 42% since the beginning of the year versus the S&P 500's decline of -15.3%.
What's Next for Neogen?
While Neogen has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Neogen: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.14 on $237.04 million in revenues for the coming quarter and $0.45 on $908.28 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 33% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, AtriCure (ATRC), is yet to report results for the quarter ended March 2025. The results are expected to be released on April 29.
This medical device maker is expected to post quarterly loss of $0.25 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
AtriCure's revenues are expected to be $123.43 million, up 13.4% from the year-ago quarter.
Should You Invest in Neogen Corporation (NEOG)?
Before you invest in Neogen Corporation (NEOG), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Neogen Corporation (NEOG) : Free Stock Analysis Report
AtriCure, Inc. (ATRC) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Neogen (NEOG) Lags Q3 Earnings and Revenue Estimates

(RTTNews) - Neogen Corp. (NEOG), a food safety solutions company, on Wednesday announced that Chief Executive Officer and President John Adent will step down.
Shares of Neogen are dropping in the pre-market trading.
Adent is expected to serve in the role until a replacement.
The company's Board of Directors has created a special committee to lead the search for the company's next CEO.
In the pre-market trading, Neogen is 14.63% lesser at $6.01 on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Neogen CEO John Adent To Step Down, Stock Fell In Pre-market

NEOGEN ($NEOG) posted quarterly earnings results on Wednesday, April 9th. The company reported earnings of $0.10 per share, missing estimates of $0.11 by $0.01. The company also reported revenue of $220,980,000, missing estimates of $229,381,680 by $-8,401,680.
You can see Quiver Quantitative's $NEOG stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
NEOGEN Insider Trading Activity
NEOGEN insiders have traded $NEOG stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $NEOG stock by insiders over the last 6 months:
JOHN EDWARD ADENT (CEO) has made 2 purchases buying 37,535 shares for an estimated $454,176 and 0 sales.
DAVID H. NAEMURA (CFO) purchased 14,800 shares for an estimated $164,428
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
NEOGEN Hedge Fund Activity
We have seen 144 institutional investors add shares of NEOGEN stock to their portfolio, and 156 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
SELECT EQUITY GROUP, L.P. removed 3,845,047 shares (-29.0%) from their portfolio in Q4 2024, for an estimated $46,678,870
UBS GROUP AG added 3,357,298 shares (+1931.6%) to their portfolio in Q4 2024, for an estimated $40,757,597
CLARKSTON CAPITAL PARTNERS, LLC added 2,866,666 shares (+inf%) to their portfolio in Q4 2024, for an estimated $34,801,325
VANGUARD GROUP INC added 1,928,491 shares (+9.8%) to their portfolio in Q4 2024, for an estimated $23,411,880
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,521,560 shares (+27.2%) to their portfolio in Q4 2024, for an estimated $18,471,738
BAILLIE GIFFORD & CO removed 1,478,216 shares (-13.2%) from their portfolio in Q4 2024, for an estimated $17,945,542
DIMENSIONAL FUND ADVISORS LP added 1,345,056 shares (+24.0%) to their portfolio in Q4 2024, for an estimated $16,328,979
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
NEOGEN Analyst Ratings
Wall Street analysts have issued reports on $NEOG in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
Guggenheim issued a "Buy" rating on 12/19/2024
To track analyst ratings and price targets for NEOGEN, check out Quiver Quantitative's $NEOG forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

NEOGEN Earnings Results: $NEOG Reports Quarterly Earnings

(RTTNews) - Below are the earnings highlights for Neogen Corp. (NEOG):
Earnings: -$11 million in Q3 vs. -$2 million in the same period last year. EPS: -$0.05 in Q3 vs. -$0.01 in the same period last year. Excluding items, Neogen Corp. reported adjusted earnings of $20.9 million or $0.10 per share for the period.
Revenue: $221 million in Q3 vs. $228.8 million in the same period last year.
-Guidance: Full year revenue guidance: Approx. $895 Mln
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Neogen Corp. Q3 Earnings Summary

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the JPMorgan BetaBuilders US Mid Cap Equity ETF (Symbol: BBMC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $114.61 per unit.
With BBMC trading at a recent price near $94.03 per unit, that means that analysts see 21.88% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of BBMC's underlying holdings with notable upside to their analyst target prices are CRISPR Therapeutics AG (Symbol: CRSP), Neogen Corp (Symbol: NEOG), and Hecla Mining Co (Symbol: HL). Although CRSP has traded at a recent price of $43.84/share, the average analyst target is 89.23% higher at $82.96/share. Similarly, NEOG has 46.75% upside from the recent share price of $9.54 if the average analyst target price of $14.00/share is reached, and analysts on average are expecting HL to reach a target price of $7.56/share, which is 37.49% above the recent price of $5.50. Below is a twelve month price history chart comparing the stock performance of CRSP, NEOG, and HL:
Below is a summary table of the current analyst target prices discussed above:
Name
Symbol
Recent Price
Avg. Analyst 12-Mo. Target
% Upside to Target
JPMorgan BetaBuilders US Mid Cap Equity ETF
BBMC
$94.03
$114.61
21.88%
CRISPR Therapeutics AG
CRSP
$43.84
$82.96
89.23%
Neogen Corp
NEOG
$9.54
$14.00
46.75%
Hecla Mining Co
HL
$5.50
$7.56
37.49%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
Also see:
Funds Holding EERN
GVV Videos
SPHS Options Chain
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

BBMC's Underlying Holdings Could Mean 22% Gain Potential

Neogen Corporation NEOG recently announced the launch of its new Neogen Molecular Detection Assay 2 – Quantitative Salmonella (MDA2QSAL96). This assay helps overcome certain limitations of existing solutions with improved sensitivity and accuracy and an easy-to-use workflow.
Molecular Detection Assay 2 - Quantitative Salmonella is the latest addition to the company’s Molecular Detection System pathogen testing platform.
NEOG’s Likely Stock Trend Following the News
Following the announcement, shares of NEOG moved 2.1% north to $11.60 yesterday.
Neogen consistently demonstrates core growth within the Food Safely segment by bringing advanced technologies to address the challenging needs in the poultry industry. Earlier in fiscal 2024, the company launched its new Molecular Detection Assay 2 – Salmonella Enteritidis/Salmonella Typhimurium (MDA2SEST) and CelluSmart technology (from Megazyme by Neogen). Henceforth, we expect market sentiment to remain positive surrounding the announcement of the latest development.
NEOG currently has a market capitalization of $2.52 billion. The Zacks Consensus Estimate for fiscal 2025 revenues is pegged at $935.1 million, which suggests 1.2% growth from the fiscal 2024 reported number.
About NEOG’S Molecular Detection Assay 2 – Quantitative Salmonella
The Neogen MDA2QSAL96 kit integrates qualitative pathogen testing solutions and Quantitative Rapid Enrichment Dehydrated media designed to enable controlled growth rates for quantitation, allowing poultry producers to verify the effectiveness of their interventions. This quantitative method delivers excellent consistency and sensitivity on poultry rinses and ground poultry meat with an easy-to-use workflow that saves time and resources.
About NEOG’s Molecular Detection System
Other than the MDA2QSAL96 kit, Neogen’s Molecular Detection System platform contains several next-generation assays, including Salmonella, Salmonella Enteriditis and Typhimurium, E. coli O157 (including H7), Listeria spp., Listeria monocytogenes, Campylobacter, STEC gene screen (stx and eae), STEC gene screen (stx) and Cronobacter.
The award-winning Neogen Molecular Detection System platform is used by food processors, universities, governments and contract testing laboratories in more than 40 countries. It is powered by a combination of advanced technologies — isothermal DNA amplification and bioluminescence detection — to provide a pathogen testing solution that is fast, accurate, easy to use and affordable.
The U.S. Department of Agriculture Food Safety and Inspection Service (USDA FSIS) named the Neogen Molecular Detection System as the primary method for detecting Salmonella, Listeria monocytogenes and Listeria spp.
Image Source: Zacks Investment Research
Industry Prospects Favor Neogen
Per a report from Modor Intelligence, the microbiology testing market was worth $5.65 billion in 2024 and is expected to reach $8.78 billion by 2029 at a compound annual growth rate of 9.2% during the period. Technological advancements in microbiology testing and the increasing incidence of fungal infections are propelling the market's growth.
Other Recent Developments by Neogen
In December 2024, Neogen introduced the Petrifilm Bacillus cereus Count Plate. This solution offers food safety professionals a simple, reliable, and efficient testing method for Bacillus cereus. Petrifilm Bacillus cereus Count Plate is the latest addition to the company’s Petrifilm product line.
Price Performance
In the past year, NEOG’s shares have lost 31.3% against the industry’s 9.7% growth.
Zacks Rank and Key Picks
Neogen currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Veracyte VCYT, ResMed RMD and Omnicell OMCL.
Veracyte, carrying a Zacks Rank of #1 (Strong Buy) at present, has an estimated earnings growth rate of 65.8% for 2025. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 520.58%. Veracyte’s shares have risen 49.2% in the past year compared with the industry’s 5.5% growth.
ResMed, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 21.1% for 2025. RMD’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.41%. Its shares have risen 34.1% compared with the industry’s 7.7% growth in the past year.
Omnicell, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 72.7% for fourth-quarter 2024. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 121.74%. OMCL’s shares have risen 26.4% against the industry’s 15.7% decline in the past year.
Just Released: Zacks Top 10 Stocks for 2025
Hurry – you can still get in early on our 10 top tickers for 2025. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2025. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Omnicell, Inc. (OMCL) : Free Stock Analysis Report
ResMed Inc. (RMD) : Free Stock Analysis Report
Neogen Corporation (NEOG) : Free Stock Analysis Report
Veracyte, Inc. (VCYT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.